There is a surge in interest in developing synthetic macrocycles in recent years as judged by their rise in a number of clinical trials as well as a number of new biotech exploring this space and number of deals made. Macrocycles are defined as molecules containing at least one ring composed of 8 or more atoms. There are number of examples of macrocyclic drug molecules, originating from natural products such as erythromycin, rapamycin, epothilone. Macrocycles bring unique advantages of drug-likeness of small molecules and high selectivity profile like antibodies. Their size and complexity allow them to interact with targets with a number of spatially distributed interactions. The ring structures of macrocycles provide metabolic stability, thus enhancing physicochemical properties and oral bioavailability. AlloMek plans to explore macrocycles for applications in rare diseases related to laminopathies and rasopathies.